This test is most useful if any of these apply to you.
If you're being followed for a known neuroendocrine tumor, chromogranin A may add information to your scans and symptoms, particularly if it was raised when the tumor was diagnosed. Its usefulness varies. Some tumors release little of the protein, while heartburn medication, kidney disease, and other conditions can raise it without a tumor.
Chromogranin A, usually shortened to CgA, is stored inside small sacs in neuroendocrine cells and released alongside their hormones. Neuroendocrine cells make hormones in response to nerve and chemical signals. They're found in the gut, pancreas, lungs, adrenal glands, and other tissues.
Your blood concentration depends on how much these cells release and how quickly your body clears the protein and its fragments. A tumor can increase that release, but the result isn't a direct measurement of tumor size or the total amount of neuroendocrine tissue.
This test measures CgA in serum obtained from a blood draw. The laboratory breaks the protein into smaller pieces, separates them, and measures a characteristic piece with an instrument that identifies molecules by their mass. This method is called LC-MS/MS. That signal is used to calculate the protein concentration.
Many other CgA tests use antibodies. Different methods recognize or quantify different parts of the protein and can produce substantially different results. LC-MS avoids dependence on antibody binding, but results from different methods aren't interchangeable.
Much of the clinical evidence about CgA comes from serum or plasma antibody assays. Those studies support the biological associations described below, but their numerical results and monitoring rules cannot be transferred directly to serum LC-MS. The LC-MS validation study established laboratory performance; it didn't establish how accurately this method detects tumor progression.
Neuroendocrine tumors are often called NETs. They can arise in the small intestine, pancreas, lungs, stomach, rectum, and other sites. Many grow slowly, though their behavior varies. Some release hormones that cause flushing, diarrhea, wheezing, or other symptoms. Others cause no hormone-related symptoms.
CgA can be raised in tumors that cause hormone-related symptoms and in those that don't. Studies using antibody assays have generally found higher concentrations with more extensive disease, including spread to the liver, but the relationship varies by tumor type. A result within the laboratory's range cannot rule out a NET, and an elevated result cannot establish the diagnosis.
Other tumors can also release CgA, including pheochromocytomas, medullary thyroid cancers, some pituitary tumors, and some cancers with neuroendocrine features. This broad distribution limits its ability to identify where a tumor started. Tests for the particular hormones a tumor releases often provide more specific information.
CgA is sometimes followed when a known NET previously produced an elevated result. Studies using antibody assays have found that changes can accompany changes in disease activity, and occasionally precede visible recurrence. But early detection of recurrence is unreliable, and it hasn't been established that acting on CgA changes alone improves outcomes.
A prospective study using a serum antibody assay found that its predefined rise identified only about a third of follow-up visits where scans showed progression. This supports treating CgA as additional information alongside imaging. That performance estimate applies to the antibody assay studied, rather than establishing the accuracy of this LC-MS test.
Current expert guidance advises against routinely using CgA to choose or change treatment for advanced gastrointestinal and pancreatic neuroendocrine tumors. Treatment decisions depend on the tumor's location, growth, tissue findings, symptoms, and imaging.
A trend is most informative when previous results have agreed with the behavior of your particular tumor. A persistent rise deserves review, but medication changes, kidney function, sample handling, and a switch in assay can all produce a misleading pattern. Stable or falling CgA can coexist with tumor progression.
A pretreatment value helps put later results in context. If that value wasn't collected, subsequent measurements can still establish a comparison point. The absence of an earlier result doesn't make every later result useless.
Evidence-backed interventions that affect your Chromogranin A level
Chromogranin A is best interpreted alongside these tests.